Europe Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels,

Europe Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type (Vitamin D and Calcium Supplement, Protein Supplement, Vitamin B12 Supplement, and Others) and Distribution Channel (Pharmacies, Retail Channels, Online Channels, and Others)

The Europe sarcopenia treatment market was valued at US$ 993.46 million in 2022 and is expected to reach US$ 1,467.81 million by 2030; it is estimated to register a CAGR of 5.0% from 2022 to 2030. Rise in Malnutrition and Vitamin Deficiency Among Adults Boosts Europe Sarcopenia Treatment Market Malnutrition is one of the major risk factors for sarcopenia. According to the WHO, approximately 2.3 billion adults worldwide were undernourished as of 2021, representing nearly 30% of the global population. Among the reported risk factors, protein-energy deficiency is a frequent cause of sarcopenia. Further, vitamin D deficiency or insufficiency is positively associated with an increased risk of multiple illnesses, such as cancer, obesity, cardiovascular disease, and sarcopenia. According to the National Institutes of Health (NIH), nearly 50% of the world's population suffers from vitamin D insufficiency, and ~1 billion people are vitamin D deficient. Europe Sarcopenia Treatment Market Overview The sarcopenia treatment market in Europe is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global sarcopenia treatment market and is estimated to register a notable CAGR during the forecast period. Germany is an attractive market due to its innovative approach toward healthcare. According to the Federal Statistical Office, health expenditure in this country amounted to US$ 474 billion in 2021. The awareness of sarcopenia and sarcopenic obesity (SO) is gradually increasing in aging societies across Germany. Sarcopenia and SO are comparatively uncommon (<5%) among German men aged 70 and above. Therefore, an upsurge in the cases of orthopedic disorders, coupled with the rising demand for nutritional supplements, drives the growth of the sarcopenia treatment market in Germany. Europe Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million) Europe Sarcopenia Treatment Market Segmentation The Europe sarcopenia treatment market is categorized into treatment type, distribution channel, and country. Based on treatment type, the Europe sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Europe sarcopenia treatment market share in 2022. In terms of distribution channel, the Europe sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Europe sarcopenia treatment market share in 2022. By country, the Europe sarcopenia treatment market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe sarcopenia treatment market share in 2022. Abbott Laboratories, Amway Corp, Bayer AG, GSK Plc, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, and Sanofi SA are some of the leading companies operating in the Europe sarcopenia treatment market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe sarcopenia treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe sarcopenia treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe sarcopenia treatment market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution. Show more